{"id":"39727f43-50a9-5e9a-8562-6874a07a8f77","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:mdd-alcar-low","predicate":"reported_relationship","statement":"Patients with major depressive disorder had lower plasma ALCAR in the 2018 case-control study.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"c6e54fde-f47e-52b4-94fd-d6f588cdcef4","mechanism_event_label":"Patients with major depressive disorder had lower plasma ALCAR in the 2018 case-control study.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"b59eb6f8-bd3b-50e6-b5d7-19cd60b27b62","slug":"human-mdd-plasma-alcar","display_name":"Plasma ALCAR in human major depressive disorder","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c6e54fde-f47e-52b4-94fd-d6f588cdcef4","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:mdd-alcar-low-event","event_type":"experimental_observation","label":"Patients with major depressive disorder had lower plasma ALCAR in the 2018 case-control study.","description":"### mdd-alcar-low\n\nPatients with major depressive disorder had lower plasma ALCAR in the 2018 case-control study.\nExploratory severity, onset and treatment-resistance associations were reported. The study did not measure neuronal nuclear acetyl-CoA, Grm2 promoter acetylation or randomized supplementation response.\nModel and exposure: 71 MDD participants and 45 controls across two centers; observational human plasma measurements.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyl-l-carnitine deficiency in patients with major depressive disorder. | 2018 | https://pubmed.ncbi.nlm.nih.gov/30061399/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6112703/ | https://doi.org/10.1073/pnas.1801609115 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"b59eb6f8-bd3b-50e6-b5d7-19cd60b27b62","slug":"human-mdd-plasma-alcar","display_name":"Plasma ALCAR in human major depressive disorder","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"71 MDD participants and 45 controls across two centers; observational human plasma measurements.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Patients with major depressive disorder had lower plasma ALCAR in the 2018 case-control study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Acetyl-l-carnitine deficiency in patients with major depressive disorder. | https://pubmed.ncbi.nlm.nih.gov/30061399/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6112703/ | https://doi.org/10.1073/pnas.1801609115","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference mdd-alcar-low; Exploratory severity, onset and treatment-resistance associations were reported. The study did not measure neuronal nuclear acetyl-CoA, Grm2 promoter acetylation or randomized supplementation response.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"72ce49ab-a345-5ac4-8567-104658786e2e","evidence_kind":"source_excerpt","locator":"Lines 571-577","start_line":571,"end_line":577,"excerpt":"### mdd-alcar-low\n\nPatients with major depressive disorder had lower plasma ALCAR in the 2018 case-control study.\nExploratory severity, onset and treatment-resistance associations were reported. The study did not measure neuronal nuclear acetyl-CoA, Grm2 promoter acetylation or randomized supplementation response.\nModel and exposure: 71 MDD participants and 45 controls across two centers; observational human plasma measurements.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyl-l-carnitine deficiency in patients with major depressive disorder. | 2018 | https://pubmed.ncbi.nlm.nih.gov/30061399/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6112703/ | https://doi.org/10.1073/pnas.1801609115 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"71 MDD participants and 45 controls across two centers; observational human plasma measurements.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}